Consistent with our results, sitagliptin (600 mg/kg/day, 90 days, PO) reduced cognitive impairment and brain damage in rats suffering from chronic cerebral hypo-perfusion by decreasing inflammation via attenuating IL-1β, TNF-α, and other inflammatory factors (42). The gene discussed is TNF; the disease is Cognitive impairment.